Clinical Lab Automation Market Size & Forecast
The Clinical Lab Automation Market is projected to reach $3.72 billion by 2030, at a CAGR of 7.8% from 2023 to 2030. Clinical lab automation offers numerous advantages, including the enhancement of diagnostic speed and accuracy, reduction of human errors, cost savings, and increased productivity. Implementing automation in clinical laboratories enables the efficient handling of larger workloads without the need for proportional increases in staffing.
The growth of this market can be attributed to the rising global geriatric population, the increasing prevalence of infectious diseases, and technological advancements in clinical laboratory instruments. However, the high costs of advanced clinical lab automation equipment, coupled with funding and infrastructure limitations in developing countries, restrain the growth of this market.
Furthermore, the increasing demand for automated instruments, technological advancements in molecular diagnostics, and emerging economies are expected to create market growth opportunities. However, factors such as high equipment maintenance and repair costs and concerns over the security and privacy of patient data pose challenges for the market’s growth.
Increasing Prevalence of Infectious & Chronic Diseases
The world is becoming increasingly connected, and infectious diseases are spreading rapidly due to cross-border travel. For instance:
-
According to the World Health Organization (WHO), in 2021, an estimated 10.6 million people fell ill with tuberculosis (TB), an increase of 4.5% over 2020. In the same year, approximately 1.6 million people died from TB. The burden of Drug-resistant TB (DR-TB) also increased by 3% between 2020 and 2021, with 450,000 cases of Rifampicin-resistant TB (RR-TB) recorded in 2021.
-
Globally, there were approximately 38.4 million people with HIV in 2021, a significant increase from 33.6 million in 2015. Of these, 36.7 million were adults, and 1.7 million were children (<15 years old). An estimated 1.5 million individuals worldwide acquired HIV in 2021. There were 20.6 million people with HIV (53%) in Eastern and Southern Africa, 5 million (13%) in Western and Central Africa, 6 million (15%) in Asia and the Pacific, and 2.3 million (5%) in Central Europe and North America.
- In 2020, WHO estimated 374 million new STI cases globally—chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million), and trichomoniasis (156 million).
- According to WHO, as of 10th November 2022, there were 630,601,291 confirmed cases of COVID-19 globally, a massive increase from 3,432,070 on 8th November 2021.
- The WHO estimates that 296 million people had chronic hepatitis B infection in 2019, with 1.5 million new cases recorded each year. As of July 2023, 58 million people worldwide had hepatitis C.
Diagnostic tests are crucial in the medical care of patients who have these diseases. Thus, the increasing prevalence of infectious & chronic diseases is expected to boost the demand for diagnostics, increasing the adoption of automated diagnostic devices and products.
Shortage of Skilled Professionals Leading to the Increased Use of Automated Systems
In recent years, laboratories and healthcare institutions have witnessed a major shortage of laboratory workers/professionals. According to the U.S. Bureau of Labor Statistics, the demand for clinical laboratory technicians and technologists is expected to grow by 5% from 2022 to 2032. This increasing demand is attributed to the aging workforce and the decreasing number of accredited training programs. To tackle this challenge, laboratories and hospitals can opt for automated devices such as automated PCR instruments and automated analyzers. The utilization of automated systems has increased since the COVID-19 pandemic. Market players are also focused on the development of automated systems for clinical laboratories. For instance, in October 2020, Kawasaki Heavy Industries, Ltd. (Japan) collaborated with Medicaroid Corporation (Japan) and Sysmex Corporation (Japan) to launch PCR testing services delivered using a mobile, automated system operated by robots to reduce the workload on healthcare professionals and ensure their safety during the pandemic.
Automation can significantly increase the efficiency of laboratories. Clear Labs, Inc. (U.S.), a private genomic testing company, offers a fully automated, next-generation sequencing platform for clinical diagnostics. The company offers Clear Dx and Clear Safety Automated Whole Genome Sequencing (WGS) instruments, which use sequencing, robotics, and cloud-based analytics to detect various types of infections and conditions. Clear Dx was initially used to screen for salmonella and listeria in food products but was redirected to detect pathogens and microorganisms during the COVID-19 pandemic.
The Systems Segment is Expected to Account for the Largest Share of the Market in 2023
Based on product, the clinical lab automation market is segmented into systems and clinical lab automation software. In 2023, the systems segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the benefits of clinical lab automation systems, which facilitate procedures without manual intervention, enhancing laboratory testing capabilities. These systems mitigate repetitive tasks and errors, resulting in increased throughput and efficiency, ultimately improving the quality of test results.
The Hospital Laboratories Segment is Expected to Account for the Largest Share of the Market in 2023
Based on end user the clinical lab automation market is segmented into hospital laboratories, diagnostic laboratories, and other end users. In 2023, the hospital laboratories segment is expected to account for the largest share of the market. Hospital laboratories automate clinical diagnostics to minimize human interventions in laboratory procedures. Automation improves the ordering, testing, and reporting of diagnostic tests in hospitals. Furthermore, the rising healthcare expenditures, the increasing prevalence of chronic diseases, increasing sample loads in hospitals, and improving healthcare infrastructure in developing countries drive the demand for lab automation systems. These factors contribute to the large market share of this segment.
Asia-Pacific: Fastest-growing Regional Market
Asia-Pacific is slated to register the highest CAGR in the clinical lab automation market during the forecast period. The growth of this market is primarily driven by the increasing investment by healthcare providers towards infrastructure improvement, the need to manage the growing burden of infectious diseases, the rising demand for clinical testing, supportive government initiatives to improve the accessibility to diagnostic services, and the need to establish more diagnostic laboratories.
Clinical Lab Automation Market: Key Companies
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players over the past few years. The key players profiled in the global clinical lab automation market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Revvity, Inc. (Formerly known as PerkinElmer, Inc.) (U.S.), F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), Waters Corporation (U.S.), Tecan Group Ltd. (Switzerland), Siemens Healthineers AG (Germany), Becton, Dickinson, and Company (U.S.), Abbott Laboratories (U.S.), Hudson Robotics, Inc. (U.S.), and Hamilton Company (U.S.).
Clinical Lab Automation Market Report Summary:
Particulars
|
Details
|
Number of Pages
|
209
|
Format
|
PDF
|
Forecast Period
|
2023-2030
|
Base Year
|
2022
|
CAGR
|
7.8%
|
Estimated Market Size (Value)
|
$3.72 billion by 2030
|
Segments Covered
|
By Product
- Systems
- Automated Liquid Handling Systems
- Automated ELISA Systems
- Automated Nucleic Acid Purification Systems
- Automated Microplate Readers
- Other Systems
(Note: Other systems include automated incubators, automated cell counters, and cell imaging systems.)
- Clinical Lab Automation Software
By End User
- Hospital Laboratories
- Diagnostic Laboratories
- Other End Users
(Note: Other end users include blood banks, forensic labs, and clinical research organizations.)
|
Countries Covered
|
North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, RoE), Asia-Pacific (China, Japan, India, RoAPAC), Latin America, and the Middle East & Africa.
|
Key Companies
|
Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Revvity, Inc. (Formerly known as PerkinElmer, Inc.) (U.S.), F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), Waters Corporation (U.S.), Tecan Group Ltd. (Switzerland), Siemens Healthineers AG (Germany), Becton, Dickinson, and Company (U.S.), Abbott Laboratories (U.S.), Hudson Robotics, Inc. (U.S.), and Hamilton Company (U.S.)
|
Key questions answered in the report: